Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Salinas

Otolaryngology Henderson, NV Medical Doctor

NPI 1497984835 CMS profile 1060746

3195 Saint Rose Pkwy Ste 210, Henderson, NV 89052

Open in the dashboard

General payments

$1,023

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Salinas of Henderson, NV is reported in the CMS Open Payments database as having received $1,023 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47 2
2024 General $251 4
2023 General $128 6
2022 General $211 12
2021 General $200 11
2020 General $111 6
2019 General $74 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Salinas
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Jonathan Salinas were reported at $47. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Jonathan Salinas Otolaryngology median Middle half National median
2019 $74 $194 $82–$512 $163
2020 $111 $118 $42–$280 $114
2021 $200 $167 $63–$444 $132
2022 $211 $216 $84–$545 $149
2023 $128 $235 $93–$588 $160
2024 $251 $280 $111–$699 $164
2025 $47 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. OptiNose US, Inc. $377 23 payments
  2. Olympus America Inc. $155 1 payment
  3. Regeneron Healthcare Solutions, Inc. $147 6 payments
  4. Genzyme Corporation $95 5 payments
  5. Acclarent, Inc $77 3 payments
  6. Inspire Medical Systems, Inc. $51 2 payments
  7. AstraZeneca Pharmaceuticals LP $32 1 payment
  8. Phadia US Inc. $27 1 payment
  9. GlaxoSmithKline, LLC. $19 1 payment
  10. Ethicon US, LLC $16 1 payment
  11. Other $25 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,023 46 payments
Products named General payments · program years 2019–2025
  1. Xhance $377 23 payments
  2. Olympus $155 1 payment
  3. RHINO-LARYNGO FIBERSCOPE $155 1 payment
  4. DUPIXENT Inflammation And Immunology $147 6 payments
  5. DUPIXENT Immunology $95 5 payments
  6. INSPIRE $51 2 payments
  7. Acclarent Aera $45 1 payment
  8. ImmunoCAP $27 1 payment
  9. NUCALA $19 1 payment
  10. INSPIRA AIR Balloon Dilation System $17 1 payment
  11. Other $57 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

404

Median for Otolaryngology: 297

Drug cost

$6,955

Median for Otolaryngology: $6,314

Branded share of claims

7.9%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 125 $3,604
Azelastine-Fluticasone Azelastine/Fluticasone Brand 15 $1,356
Ofloxacin Generic 12 $388
Pantoprazole Sodium Generic 109 $387
Fluticasone Propionate Generic 31 $266
Azelastine Hcl Generic 13 $265
Fluconazole Generic 43 $254
Clotrimazole Generic 13 $241
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 17 $82
Famotidine Generic 12 $58

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$308,515

Medicare's payments for the services billed

Medicare patients

538

Average age 75

Services billed

3,038

286 women, 252 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 36%
Diabetes 33%
COPD 27%
Chronic kidney disease 26%
Atrial fibrillation 22%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record